Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Markstein

Showing results (31-40 of 45) with videos related to

Pageof 5
Sort By:
Molecular Pharmacology|May 1, 1989
Characterization of dopamine receptor subtypes by comparative structure-activity relationships: dopaminomimetic activities and solid state conformation of monohydroxy-1,2,3,4,4a,5,10,10a-octahydrobenz[g]quinolines and its implications for a rotamer-based dopamine receptor modelM P Seiler, R Markstein, M D Walkinshaw, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|August 4, 1999
Pharmacological characterisation of 5-HT receptors positively coupled to adenylyl cyclase in the rat hippocampusR Markstein, M Matsumoto, C Kohler, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|July 1, 1995
Effect of adding the D-1 agonist CY 208-243 to chronic bromocriptine treatment of MPTP-monkeys: regional changes of brain dopamine receptorsC Gagnon, B Gomez-Mancilla, R Markstein, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|May 1, 1985
DPI 201-106, a novel cardioactive agent. Combination of cAMP-independent positive inotropic, negative chronotropic, action potential prolonging and coronary dilatory propertiesG Scholtysik, R Salzmann, R Berthold, et al.
Experimental and Toxicologic Pathology : Official Journal of the Gesellschaft Fur Toxikologische Pathologie|December 6, 2005
Effects of anti-glaucoma drugs timolol and GLC756, a novel mixed dopamine D2 receptor agonist and D1 receptor antagonist, on endotoxin-induced-uveitis and -arthritis in ratsU W Laengle, M Court, R Markstein, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|April 1, 1993
Effect of adding the D1 agonist CY 208-243 to chronic bromocriptine treatment. I: Evaluation of motor parameters in relation to striatal catecholamine content and dopamine receptorsB Gomez-Mancilla, R Boucher, C Gagnon, et al.
Journal of Neural Transmission|January 1, 1987
Biochemical, behavioural, and endocrine effects of CK 204-933, a novel 8 beta-ergoleneR Markstein, A Enz, J M Vigouret, et al.
Life Sciences|January 13, 1986
Pharmacological profile of the abeorphine 201-678, a potent orally active and long lasting dopamine agonistA L Jaton, R K Giger, J M Vigouret, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|January 1, 1996
SDZ PSD 958, a novel D1 receptor antagonist with potential limbic selectivityR Markstein, P Gull, C Rüdeberg, et al.
The Journal of Clinical Endocrinology and Metabolism|March 1, 1992
Somatostatin inhibits the activity of adenylate cyclase in cultured human meningioma cells and stimulates their growthJ W Koper, R Markstein, C Kohler, et al.
Pageof 5

Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
Molecular Pharmacology|May 1, 1989
Characterization of dopamine receptor subtypes by comparative structure-activity relationships: dopaminomimetic activities and solid state conformation of monohydroxy-1,2,3,4,4a,5,10,10a-octahydrobenz[g]quinolines and its implications for a rotamer-based dopamine receptor modelM P Seiler, R Markstein, M D Walkinshaw, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|August 4, 1999
Pharmacological characterisation of 5-HT receptors positively coupled to adenylyl cyclase in the rat hippocampusR Markstein, M Matsumoto, C Kohler, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|July 1, 1995
Effect of adding the D-1 agonist CY 208-243 to chronic bromocriptine treatment of MPTP-monkeys: regional changes of brain dopamine receptorsC Gagnon, B Gomez-Mancilla, R Markstein, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|May 1, 1985
DPI 201-106, a novel cardioactive agent. Combination of cAMP-independent positive inotropic, negative chronotropic, action potential prolonging and coronary dilatory propertiesG Scholtysik, R Salzmann, R Berthold, et al.
Experimental and Toxicologic Pathology : Official Journal of the Gesellschaft Fur Toxikologische Pathologie|December 6, 2005
Effects of anti-glaucoma drugs timolol and GLC756, a novel mixed dopamine D2 receptor agonist and D1 receptor antagonist, on endotoxin-induced-uveitis and -arthritis in ratsU W Laengle, M Court, R Markstein, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|April 1, 1993
Effect of adding the D1 agonist CY 208-243 to chronic bromocriptine treatment. I: Evaluation of motor parameters in relation to striatal catecholamine content and dopamine receptorsB Gomez-Mancilla, R Boucher, C Gagnon, et al.
Journal of Neural Transmission|January 1, 1987
Biochemical, behavioural, and endocrine effects of CK 204-933, a novel 8 beta-ergoleneR Markstein, A Enz, J M Vigouret, et al.
Life Sciences|January 13, 1986
Pharmacological profile of the abeorphine 201-678, a potent orally active and long lasting dopamine agonistA L Jaton, R K Giger, J M Vigouret, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|January 1, 1996
SDZ PSD 958, a novel D1 receptor antagonist with potential limbic selectivityR Markstein, P Gull, C Rüdeberg, et al.
The Journal of Clinical Endocrinology and Metabolism|March 1, 1992
Somatostatin inhibits the activity of adenylate cyclase in cultured human meningioma cells and stimulates their growthJ W Koper, R Markstein, C Kohler, et al.
Pageof 5